Similar observations were made for HLA-genotyped patients with (pre)malignant cancers who were treated with a Synthetic Long Peptide Vaccine encoding HPV16, where we have found 90% agreement between the measured CD8+ T-cell responses and the predicted PEPIs, but no correlation between single HLA-binding epitopes and T-cell responses [138]. Here, CD8A is linked to cancer.